



## Our Core Strengths Create the Foundation for Diversified, Durable Growth and Dependable Performance

As a global medical technology innovator leading the way in women's health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are rooted in *The Science of Sure®*, our promise to deliver world-class certainty, precision and quality to healthcare providers and their patients.

DIVISION	CORE PRODUCTS	EXPANDING PORTFOLIO	
<p><b>DIAGNOSTIC SOLUTIONS</b></p>	 <p><b>Panther System® • Aptima® STI Assays • ThinPrep® Pap Test and Cytology Instruments</b></p>	<p><b>Aptima BV and CV/TV Assays</b></p> <ul style="list-style-type: none"> <li>Nucleic acid amplification tests.</li> <li>Used to detect the three leading causes of vaginosis and vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.</li> </ul> <p><b>Breast Cancer Index Test™</b></p> <ul style="list-style-type: none"> <li>Used to predict which breast cancer patients are likely to benefit from extended endocrine therapy.</li> <li>The only test of its kind recognized by key medical societies.</li> <li>Reimbursed by Medicare and key insurance providers.</li> </ul> <p><b>Panther Fusion® Assays</b></p> <ul style="list-style-type: none"> <li>Expand the molecular assay menu running efficiently on Panther Scalable Solutions.</li> <li>Hologic's syndromic solutions (Respiratory &amp; GI assays) enable testing tailored to the individual, reducing unnecessary use of resources and time.</li> </ul>	<p><b>Panther Fusion® and Panther Scalable Solutions</b></p> <ul style="list-style-type: none"> <li>Provide access to Hologic's full menu of molecular diagnostic tests.</li> <li>Allow labs to expand existing molecular testing capabilities.</li> <li>Increase flexibility, capacity and walkaway time.</li> </ul> <p><b>Genius Digital Cytology</b></p> <ul style="list-style-type: none"> <li>First CE-marked digital cytology platform to combine an artificial intelligence (AI) algorithm with advanced volumetric imaging technology.</li> <li>Comprehensive cervical cancer screening portfolio — from sample collection to digital diagnosis.</li> <li>Helps healthcare providers by supplying critical information needed to help guide earlier detection and better treatment decisions.</li> </ul>
<p><b>BREAST &amp; SKELETAL HEALTH SOLUTIONS</b></p>	 <p><b>3Dimensions® • Affirm® Breast Biopsy Systems • Trident® Specimen Radiography System • Localizer™ Wire-free Guidance System</b></p>	<p><b>Brevera®</b></p> <ul style="list-style-type: none"> <li>Breast biopsy system provides real-time imaging and analysis of specimens.</li> <li>Intuitive user interface and automated specimen collection.</li> <li>Streamlined, accurate procedures reduce a patient's time under breast compression.</li> </ul> <p><b>Genius AI™</b></p> <ul style="list-style-type: none"> <li>Supports radiologists in improving accuracy and consistency of breast cancer detection.</li> <li>Designed to maximize effectiveness of 3D mammography.</li> <li>Software is fully integrated on 3Dimensions systems.</li> </ul>	<p><b>Interventional Needles</b></p> <ul style="list-style-type: none"> <li>Portfolio of tissue-acquisition needles that function with stereotactic and ultrasound systems.</li> <li>Provide ease of use with world-class accuracy, consistency and efficiency.</li> </ul> <p><b>Tissue Markers</b></p> <ul style="list-style-type: none"> <li>Serve a fast-expanding market of products for breast conserving surgery.</li> <li>Minimally invasive innovations that enable imaging and radiation treatment.</li> <li>Completed Endomagetics acquisition in July 2024, adding additional localization and tracing products to portfolio.</li> </ul>
<p><b>GYN SURGICAL SOLUTIONS</b></p>	 <p><b>NovaSure® • MyoSure®</b></p>	<p><b>Fluent® Pro</b></p> <ul style="list-style-type: none"> <li>Fluid management system for hysteroscopies.</li> <li>Provides simplified set-up and operation.</li> <li>Advanced technology designed to increase clinical confidence.</li> </ul> <p><b>Sonata System</b></p> <ul style="list-style-type: none"> <li>Transcervical fibroid ablation for treatment of symptomatic uterine fibroids.</li> <li>Delivers a breakthrough alternative to hysterectomy and myomectomy.</li> <li>Incisionless, transcervical delivery avoids the peritoneal cavity, allowing faster recovery times.</li> </ul>	<p><b>CoolSeal® Portfolio</b></p> <ul style="list-style-type: none"> <li>Gold-standard efficacy of advanced bipolar RF vessel sealing technology.</li> <li>Versatile applications for pediatric and gynecologic procedures.</li> <li>Devices cut and dissect with precision in tight spaces and with minimal thermal footprint.</li> </ul> <p><b>Omni® Hysteroscopes</b></p> <ul style="list-style-type: none"> <li>Three interchangeable sheaths to enable flexible diagnosis and treatment with a single instrument.</li> <li>Provide a clear view of the cervical canal and uterine cavity.</li> </ul>

# Growing Performance and Growing Impact

## Hologic to be Acquired by Blackstone and TPG

- On October 21, 2025, Hologic announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG.
- Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for \$76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to \$3 per share in two payments of up to \$1.50 each, for total consideration of up to \$79 per share in cash.
- The transaction is expected to close in the first half of calendar year 2026, subject to the approval of Hologic's stockholders, the receipt of required regulatory approvals and the satisfaction of certain other customary closing conditions.
- For more information, please see the form 8-K filed with the SEC and available on the Hologic website: [Form 8-K and Agreement](#)

## Revenue Highlights 4Q25

Revenue (\$M)	4Q25	Reported Delta vs. 4Q24	CC Delta vs. 4Q24
Diagnostics	\$454.1	2.4%	1.5%
Organic Diagnostics ex. COVID-19 <sup>2</sup>	\$417.1	5.4%	4.4%
Organic Molecular Diag. ex. COVID-19 <sup>2</sup>	\$294.0	5.3%	4.5%
Breast Health	\$393.7	4.8%	4.2%
Organic Breast Health <sup>2</sup>	\$387.5	3.3%	2.7%
GYN Surgical	\$172.5	10.2%	9.5%
Organic Surgical <sup>2</sup>	\$164.8	5.3%	4.5%
Skeletal Health	\$29.2	129.9%	128.1%
<b>Total Revenue</b>	<b>\$1,049.5</b>	<b>6.2%</b>	<b>5.4%</b>
Organic Revenue <sup>2</sup>	\$1,027.7	4.9%	4.0%
Organic ex. COVID-19 <sup>3</sup>	\$998.6	6.2%	5.4%
<b>US Revenue</b>	<b>784.4</b>	<b>5.2%</b>	
<b>International Revenue</b>	<b>\$265.1</b>	<b>9.4%</b>	<b>6.0%</b>

## Financial Overview 4Q25

Non-GAAP in Millions ex. EPS	4Q25	Delta vs. 4Q24
Revenue (\$M)	\$1,049.5	6.2%
Organic Revenue <sup>2</sup>	\$1,027.7	4.9%
Organic ex. COVID-19 <sup>3</sup>	\$998.6	6.2%
Gross Margin	60.9%	(60) bps
Operating Expenses	\$311.9	0.3%
Operating Margin	31.2%	120 bps
Net Margin	24.3%	30 bps
Diluted EPS	\$1.13	11.9%
Adjusted EBITDA	\$347.0	7.2%

## Financial Results


### Net Debt & Leverage Ratio<sup>1</sup>




### Revenue & CC Growth Rates



### Non-GAAP EPS & Growth Rates



### 2025 Divisional Revenue by Geography



### Adjusted Operating Cash Flow<sup>4</sup>



### ROIC



## Purpose-Driven Company



Through our substantial commitment to R&D innovation, we generate strong financial results, allowing us to invest in groundbreaking health initiatives for women and underserved communities.



### Global Health:

- Hologic Global Women's Health Index represents the views of 94% of the world's women and girls aged 15 or older.
- Global Access Initiative provides cost-effective, high-quality diagnostic testing across sub-Saharan Africa.
- Philanthropic donations aid charitable groups focused on women's health, STEM education and social equality.

### Global Reach:

Locations in 36+ countries with direct staff and a market presence in more than 100 countries.

### Global Headquarters:

Marlborough, Massachusetts, USA.

1. Net debt is total debt minus cash; leverage ratio. 2. Organic revenue excludes Endomagnetics for July, Gynesonics, and the divested Blood and SSI businesses. 3. Total organic revenue excluding COVID-19. 4. Operating cash flow adjusted for one-time tax and litigation items.